Dice Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Dice Therapeutics

09/08/2023 03:04

* Dice Therapeutics Inc  DICE.OQ   DICE.O  is expected
to show no
change in quarterly revenue when it reports  results on August
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Dice Therapeutics
Inc is
for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Dice
Therapeutics
Inc is $48​, above​ its last closing price of $47.55. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.64       -0.65      -0.74     Missed  -14
 Mar. 31 2023  -0.58       -0.59      -0.54     Beat    7.8
 Dec. 31 2022  -0.48       -0.49      -0.51     Missed  -5​
 Sep. 30 2022  -0.60       -0.60      -0.55     Beat    8
 ​​Jun.        -0.56       -0.55      -0.58     Missed  -4.5
 30 2022                                                
 Mar. 31 2022  -0.54       -0.54      -0.50     Beat    7.4​
 Dec. 31 2021              -0.58      -0.44     Beat    24.8
 Sep. 30 2021  -0.50       -0.50      -2.30     Missed  -360
 This summary was machine generated August 9 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated